Romosozumab effect on neutrophil-to-lymphocyte ratio in post-menopausal women at high risk of fracture

Key Points

• This research examines the impact of romosozumab on systemic inflammation as measured by neutrophil-to-lymphocyte ratio in post-menopausal women at high risk for fractures.
• Twelve-month treatment with romosozumab was administered.
• Participants were post-menopausal women with severe osteoporosis.
• Neutrophil-to-lymphocyte ratio (NLR) was measured before and after treatment.
• A statistically significant reduction in NLR was observed after treatment.
• The shift in NLR indicates potential modulation of systemic inflammation.
• The clinical relevance of the reduction in NLR remains uncertain.